CA
ADMA icon

Clearstead Advisors’s ADMA Biologics ADMA Stock Holding History

Clearstead Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.94K Buy
232
+217
+1,447% +$1.98K ﹤0.01% 2487
2026
Q1 		$136 Sell
15
-7,812
-100% -$123K ﹤0.01% 2192
2025
Q4 		$143K Buy
7,827
+5,605
+252% +$94.5K ﹤0.01% 1013
2025
Q3 		$32.6K Buy
2,222
+795
+56% +$13.6K ﹤0.01% 1429
2025
Q2 		$26K Buy
1,427
+799
+127% +$16.3K ﹤0.01% 1517
2025
Q1 		$12.5K Hold
628
– – ﹤0.01% 1553
2024
Q4 		$10.8K Buy
+628
New +$11.8K ﹤0.01% 1552
2024
Q3 		– Sell
-20,000
Closed -$224K – 2040
2024
Q2 		$224K Buy
+20,000
New +$168K ﹤0.01% 790

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Clearstead Advisors's ADMA Position: Q2 2026 in Review

Clearstead Advisors increased its ADMA Biologics (ADMA) stake by 1,447% in Q2 2026, buying an estimated $1.98K and bringing the position to 232 shares worth $1.94K. The position accounts for ﹤0.01% of the portfolio, ranked #2487.

Clearstead Advisors first reported a position in ADMA in Q2 2024 and has held it in 8 quarters since. The position peaked at $224K in Q2 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Clearstead Advisors held 232 shares of ADMA Biologics worth $1.94K as of Q2 2026.
  • Clearstead Advisors bought 217 ADMA Biologics shares in Q2 2026, an estimated $1.98K.
  • ADMA Biologics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2487 holding.
  • Clearstead Advisors first reported a position in ADMA Biologics in Q2 2024 and has held it in 8 quarters since.
  • Clearstead Advisors's ADMA Biologics position peaked at $224K in Q2 2024.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.